Bonus BioGroup Ltd. (BBIXF)

[midastouch017]

Covid drug saves 47 of 50 severe patients in trial

https://www.israel21c.org/drug-saves-47-of-50-severe-covid-patients-in-trial/?utm_source=The+Weekly&utm_campaign=weekly-2021-12-01&utm_medium=email

Bonus BioGroup says its MesenCure experimental treatment resulted in 94% survival rate of trial subjects and cut hospitalization time in half.

By Abigail Klein Leichman NOVEMBER 25, 2021, 4:25 PM

Israel’s Bonus BioGroup reports a survival rate of 94 percent (47 of 50) of the severe Covid-19 patients treated with its drug product MesenCure in a Phase II, multicenter clinical trial.

Study results, soon to be published, show MesenCure treatment reduced study participants’ hospitalization period by about half compared to a control group. All these patients had life-threatening pneumonia and respiratory distress caused by Covid-19.

The data shows that MesenCure treatment reduced mortality by about 70% compared with the control group. Only two of the first 30 severe Covid-19 patients treated with MesenCure died due to Covid-19 or its complications, while 14 of 60 similar patients in the control group died.

MesenCure treatment shortened the hospitalization period of severe Covid-19 patients by eight days on average, a reduction of 45% relative to the control group.

The experimental group included women and men aged 41.4 to 77.4. About 77% of the severe Covid-19 patients treated in three hospitals with MesenCure had one or more risk factors for poor prognosis: hypertension, hyperlipidemia, obesity and Type 2 diabetes. Most were treated during the fourth Covid-19 wave in Israel, dominated by the Delta strain.

The control group received the current standard of care — anti-inflammatory drugs in combination with steroids. This regimen, according to Bonus BioGroup, reduces mortality in hospitalized Covid-19 patients only slightly, from 25.8% to 21.8%, indicating that MesenCure is four times more effective.

“We are proud of our success in leading the world to be a safer place by developing a medication for severe Covid-19 patients, thereby dramatically reducing the threat to their lives,” said Dr. Shai Meretzki, CEO of Bonus BioGroup.